New Product Release
Genovis will launch two new products, FragIT™ MicroSpin and deGlycIT™ MicroSpin during the European Antibody Engineering Congress 2010 in Geneva. Both products has been developed from Genovis’ unique enzyme techniques and target pharma-, biotechnology- and diagnostic companies that develop antibody based drugs and analysis.
Read more at:
The Product Release is attached and published at Genovis web site: www.genovis.com
Find out more, contact: Sarah Fredriksson, CEO, Genovis AB Tel: +46 46 10 12 35 email@example.com
Genovis is a biotech company on the leading edge of nanotechnology and nanoparticles. The company’s patented nano-induced magnetic transfer (NIMT®) technology was developed to facilitate effective preclinical research for the life science industry. Genovis shares are listed on Nasdaq OMX First North and Thenberg & Kinde Fondkommission is our certified adviser.